加拿大批准了lecanemab，这是一种阿尔茨海默病药物，可在18个月内减缓早期病情恶化30%，但由于成本、MRI需求和医疗瓶颈，获取受限。 Canada approves lecanemab, an Alzheimer’s drug that slows early-stage decline by 30% over 18 months, but access is limited by cost, MRI needs, and healthcare bottlenecks.

加拿大批准了lecanemab,这是第一个阿尔茨海默病治疗方法,通过向粉样蛋白斑块,在早期减缓疾病进展,在18个月内将认知能力下降约30% Canada has approved lecanemab, the first Alzheimer’s treatment shown to slow disease progression in early stages by targeting amyloid plaques, reducing cognitive decline by about 30% over 18 months. 由于脑肿胀或出血的风险,需要进行磁共振筛查和专家评价(ARIA)。 Administered via biweekly infusions, it requires MRI screening and specialist evaluation due to risks of brain swelling or bleeding (ARIA). 尽管它有前途,但由于每年高昂的成本 (约为26,000美元) 和MRI可用性和专业人员的挑战, Despite its promise, access is limited by its high annual cost—around $26,000—and challenges in MRI availability and specialist staffing. 省药物计划尚未承诺覆盖范围,引起人们对公平获取机会的担忧,因为加拿大的保健系统面临现有的瓶颈。 Provincial drug plans have not yet committed to coverage, raising concerns about equitable access as Canada’s healthcare system faces existing bottlenecks.